The work is being undertaken by subsidiary Agrima Botanicals Corp and the university's plant biologist Dr Zamir K. Punja.
Among the highlighted achievements is the identification of pathogens and molds affecting cannabis plants and DNA fingerprinting approaches for the identification of cannabis strains used in production.
Tissue culture methods have been developed that provide Ascent and its partners access to disease-free starting material from meristems and axillary buds in commercial scale volumes.
A DNA-based testing kit to distinguish male plants from female plants that were an outcome from this collaborative research is also currently on the market.
"In addition to strengthening our Intellectual Property (IP) portfolio, this project allows Ascent to develop and implement scientifically driven strategies to reduce crop loss risk and ensure batches of the highest quality by mitigating the impact of unwanted and deleterious cannabis pathogens," said Philip Campbell, CEO of Ascent Industries.
"In turn, this will help to ensure that we are able to produce exceptional products for use in our medical and consumer packaged goods.
"These results have wide-reaching applications to ours and our partner operations in Canada and abroad" concluded Campbell.